AKTX
Akari Therapeutics, Plc [AKTX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AKTX Stock Summary
Top 10 Correlated Stocks
AKTX
In the News
AKTX Financial details
Company Rating
-
Market Cap
8.01M
Income
-6.44K
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
9
Optionable
No
Shortable
Yes
Earnings
29 Apr 2024
P/E
-26.86
Forward P/E
-
PEG
11.09
P/S
-
P/B
104.6
P/C
-
P/FCF
-0.71
Quick Ratio
1.35
Current Ratio
1.15
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.69
EPS next Y
-
EPS next Q
-
EPS this Y
-8.52%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
50%
SMA50
-10%
SMA100
-18.18%
Inst Own
-
Inst Trans
-
ROA
-50%
ROE
-190%
ROC
-12.89%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.1-5.5
52W High
+265.4%
52W Low
+1727%
RSI
85
Rel Volume
2776.77
Avg Volume
12.26K
Volume
34.04M
Perf Week
423.5%
Perf Month
294.6%
Perf Quarter
32.2%
Perf Half Y
1.5%
-
-
-
-
Beta
0.965
-
-
Volatility
7.1%, 4.08%
Prev Close
0%
Price
18.27
Change
84.27%
Company Profile
- Volume Average 12.26K
- Market Capitalization 8.01M
- Employee 9
- CEO Ms. Rachelle Suzanne Jacques
- Headquarters London,GB
- IPO Date 2014-01-06
-
Website
https://www.akaritx.com 
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
